Do you want to spread the word about your organization’s solutions and services to potential clients who will be attending this event? Take advantage of the opportunity to exhibit, underwrite an educational session, host a networking event or distribute promotional items to attendees. ExL Events will work closely with you to customize a package that will suit all of your needs.
To learn more about these opportunities, please contact David Finkel, Business Development Manager, at 917.242.3898 or firstname.lastname@example.org.
ARENSIA EXPLORATORY MEDICINE
ARENSIA EXPLORATORY MEDICINE (www.arensia-em.com) is a German company with an innovative business model, designed to increase efficiency in early clinical trials by reducing the recruitment time and the number of sites/countries involved.
ARENSIA runs a network of its own state-of-the-art Exploratory Medicine Units located within the largest university hospitals in Eastern Europe. We are a niche provider focusing on clinical execution of exploratory protocols Phase 1b/2a/POC with highest degree of medical sophistication in broad variety of patient populations.
ARENSIA has a strong reputation in terms of safety and high quality of data and has repeat business with the top pharmaceutical companies.
Covance Inc., the drug development business of Laboratory Corporation of America Holdings (LabCorp) headquartered in Princeton, New Jersey, USA, is the world’s most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real®. Information on Covance’s solutions can be obtained through its website at www.covance.com.
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2017, ERT supported more than 60% of all FDA drug approvals. Pharma companies, biotechs and CROs have relied on ERT solutions in 13,000+ studies, spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly — and with confidence.
For more information, go to ert.com or follow us on LinkedIn and Twitter.
High Point Clinical Trials Center
High Point Clinical Trials Center has provided comprehensive (Phase I-III) clinical site services since 2008. Our 42,000 ft 2 facility consists of three unique units for the execution of outpatient and inpatient clinical studies. In addition to healthy normal Phase I studies, we focus on specialty populations such as Metabolic Diseases, Respiratory, CNS, Cardiovascular and Nicotine-related.
Nucleus Network conducts phase I clinical trials for international Pharmaceutical and Biotechnology Companies.
Established in 2003, Nucleus Network has successfully conducted over 500 phase I clinical trials including first-time-in human (FIH), single ascending (SAD) and multiple ascending dose (MAD), drug interaction, food effect, biosimilar, bioequivalence, thorough QTc, ethnopharmacology and absorption, distribution, metabolism, and excretion (ADME) studies.
Nucleus Network is considered the market leader for phase I clinical trials in Australia, with extensive experience with both biologic and small molecule products across multiple therapeutic areas.
Nucleus Network is co-located within a major tertiary teaching hospital and research precinct, allowing a safe environment for true first in human clinical trials but also access to key opinion leaders in therapeutic areas, and access to patient populations for phase I clinical trials.
There is also available the Australian R & D Tax Incentive that provides a 43.5% cash rebate for work performed there. Additionally, you can have FPI in about 5 weeks and the results are accepted by the FDA.
Q-Pharm is a leading Australian early-phase clinical trials company providing a broad range of high-quality clinical trial services. With a wealth of experience in clinical development and newly expanded 62-bed facilities, Q-Pharm’s highly qualified leaders and teams have successfully conducted over 400 early-phase clinical trials since 2002 to global safety and regulatory standards. Q-Pharm services include: PK/PD, SAD/MAD/Food Effect, complex First-In-Human, B/E & Biosimilars, vaccine studies, disease challenge models, clinical development and study design consultation.